Mariama Hamani
Between 6 and 9 July 2026, the Beninese Agency for Medicines and Health Products (ABMed) underwent a stringent evaluation by a panel of World Health Organization (WHO) experts. This rigorous assessment highlighted remarkable advancements, inching Benin closer to achieving the prestigious Maturity Level 3 certification—a global benchmark for pharmaceutical regulation excellence.
An in-depth review of Benin’s health regulatory framework
A high-level delegation of eight WHO specialists conducted a meticulous four-day audit of Benin’s health sector. Every aspect came under scrutiny: from drug market authorization to post-market surveillance, pharmacovigilance, and clinical trial oversight. The inspection aimed to assess how closely Benin’s regulatory processes align with international best practices.
The findings, presented on 9 July 2026 in Cotonou, were overwhelmingly positive. The evaluation confirmed significant strides in strengthening the country’s pharmaceutical supply chain, reinforcing confidence in the safety and reliability of health products circulating domestically.
What Maturity Level 3 means for Benin’s health security
In the WHO’s regulatory classification system, Maturity Level 3 signifies a nation with a robust, fully operational, and integrated pharmaceutical governance system. This status ensures that national authorities can effectively regulate all medicines within their borders, guaranteeing public access to safe, high-quality, and efficacious treatments.
Beyond health security, this certification carries substantial economic and geopolitical advantages. It enhances international trust, encourages local pharmaceutical production, and simplifies regional export opportunities. For Beninese citizens, it represents a decisive step in combating counterfeit and substandard medicines—a persistent public health threat.
A decade of reforms culminating in global recognition
The evaluation results were announced in the presence of Health Minister Professor Benjamin Hounkpatin, who praised the ABMed teams for their dedication and the transformative progress achieved. The imminent certification is no accident; it reflects years of bold structural reforms launched in 2017.
By transforming the former pharmacy directorate into an autonomous agency (ABMed) and strengthening legal frameworks, Benin laid the groundwork for this historic milestone. Minister Hounkpatin reaffirmed the government’s unwavering commitment to supporting ABMed until full WHO certification is secured.
Setting a regional benchmark in pharmaceutical governance
The stakes of this evaluation extend far beyond Benin’s borders. Upon achieving Maturity Level 3, Benin would join an elite group of West African nations—and become the second Francophone leader in the subregion after Senegal.
This achievement positions Benin as a future hub for health governance excellence in West Africa. It underscores a powerful message: with strong political will and sustained technical rigor, African nations can align their institutions with global standards, ensuring safer, more reliable health systems for all.
A new chapter in public health for Benin
The July 2026 WHO mission marks a pivotal moment in Benin’s public health history. Should the final assessment confirm Maturity Level 3, ABMed must now implement the experts’ remaining recommendations to officially secure this status. By reaching this threshold, Benin demonstrates that patient safety and pharmaceutical sovereignty are no longer distant goals—but an unfolding reality.
Boureima Amadou
